Want to see AZTA full AI Analyst Report?
AZTA Stock Chart & Stats
$28.18
-$0.47(-0.91%)
At close: 4:00 PM EST
$28.18
-$0.47(-0.91%)
Day’s Range― - ―
52-Week Range$15.93 - $41.73
Previous CloseN/A
Volume88.55K
Average Volume (3M)965.29K
Market Cap
$1.19B
Enterprise Value$866.83M
Total Cash (Recent Filing)$380.52M
Total Debt (Recent Filing)$55.71M
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Aug 11, 2026EPS Estimate
0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.95
Shares Outstanding46,092,804
10 Day Avg. Volume770,217
30 Day Avg. Volume965,289
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)0.76
Price to Sales (P/S)2.21
P/FCF Ratio34.28
Enterprise Value/Market Cap0.73
Enterprise Value/Revenue1.45
Enterprise Value/Gross Profit3.26
Enterprise Value/Ebitda-9.33
Forecast
1Y Price Target
$29.33Price Target Upside4.09% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)0.45
Revenue Forecast (FY)$600.45M
Bulls Say, Bears Say
Bulls Say
Recurring Revenue From BiorepositoriesBiorepository solutions represent a large, recurring portion of SMS and grew high single digits, providing durable, subscription-like revenues. This recurring base stabilizes cash flow, improves revenue visibility, supports margin resilience, and reduces reliance on lumpy capital-equipment sales over multiple quarters.
Very Strong Balance Sheet And LiquiditySubstantial liquidity and minimal debt give Azenta flexibility to fund remediation, invest in R&D, pursue M&A like UK Biocentre, and absorb cyclical downturns without refinancing pressure. This enhances strategic optionality and reduces bankruptcy or liquidity risk over the medium term.
Operational Improvements (ABS & RNA‑Seq)Meaningful operations gains (Azenta Business System improvements and faster RNA‑Seq) raise service reliability and throughput. Sustained operational discipline can lower costs, shorten sales cycles, enhance customer retention, and differentiate offerings, supporting margin expansion and scalable growth.
Bears Say
Large Goodwill ImpairmentsA $149M goodwill write‑down reflects materially lower expected cash flows from acquisitions and indicates prior overpayment or weakening demand. It reduces book equity, signals impaired M&A ROI expectations, and may constrain management credibility and future acquisition financing flexibility.
Automated Storage Quality Issues & Order PushoutsQuality remediation and delayed large equipment orders impair revenue conversion and backlog visibility. Prolonged equipment reliability issues can erode customer trust, depress future capital orders and related consumables/service revenue, and impose recurring remediation costs over multiple quarters.
Persistent Losses And Negative ReturnsDespite top‑line recovery, Azenta remains structurally unprofitable with negative ROE, indicating the business has not yet converted growth into sustainable profits. Ongoing losses limit reinvestment capacity, shareholder returns, and increase reliance on cash reserves unless margin drivers are persistently improved.
Azenta News
AZTA FAQ
What was Azenta, Inc.’s price range in the past 12 months?
Azenta, Inc. lowest stock price was $15.93 and its highest was $41.73 in the past 12 months.
What is Azenta, Inc.’s market cap?
Azenta, Inc.’s market cap is $1.19B.
When is Azenta, Inc.’s upcoming earnings report date?
Azenta, Inc.’s upcoming earnings report date is Aug 11, 2026 which is in 38 days.
How were Azenta, Inc.’s earnings last quarter?
Azenta, Inc. released its earnings results on May 05, 2026. The company reported -$0.04 earnings per share for the quarter, missing the consensus estimate of $0.123 by -$0.163.
Is Azenta, Inc. overvalued?
According to Wall Street analysts Azenta, Inc.’s price is currently Undervalued.
Does Azenta, Inc. pay dividends?
Azenta, Inc. pays a Quarterly dividend of $0.1 which represents an annual dividend yield of N/A. See more information on Azenta, Inc. dividends here
What is Azenta, Inc.’s EPS estimate?
Azenta, Inc.’s EPS estimate is 0.1.
How many shares outstanding does Azenta, Inc. have?
Azenta, Inc. has 46,092,804 shares outstanding.
What happened to Azenta, Inc.’s price movement after its last earnings report?
Azenta, Inc. reported an EPS of -$0.04 in its last earnings report, missing expectations of $0.123. Following the earnings report the stock price went down -25.315%.
Which hedge fund is a major shareholder of Azenta, Inc.?
Currently, no hedge funds are holding shares in AZTA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Azenta Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$29.33 (4.09% Upside)
$29.33 (4.09% Upside)
Blogger Sentiment
Bullish
AZTA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 476.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $163.8K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-0.83%
12-Months-Change
Fundamentals
Return on Equity
-10.69%
Trailing 12-Months
Asset Growth
-6.76%
Trailing 12-Months
Company Description
Azenta, Inc.
Azenta, Inc. is a global leader specializing in advanced solutions for the discovery, handling, and preservation of life science samples. The company's operations span across North America, Europe, Asia Pacific (including China), and other international markets. Its business is structured into two main reportable segments: Life Sciences Products and Life Sciences Services. The Life Sciences Products division supplies sophisticated automated systems for the cold storage of chemical compounds and biological specimens. This segment also provides crucial equipment for sample preparation and manipulation, along with various consumables and specialized instruments that empower customers to effectively manage samples throughout their entire research and development workflows. Conversely, the Life Sciences Services segment offers a comprehensive suite of programs for sample management, integrated cold chain logistics, cutting-edge informatics, and a range of sample-centric laboratory services. These offerings are vital for propelling scientific research and accelerating drug development. Key services include secure sample banking, advanced genomic sequencing, gene synthesis, laboratory processing, detailed laboratory analysis, biospecimen acquisition, and other essential support functions. Azenta caters to a diverse client base within the life sciences sector, encompassing pharmaceutical companies, biotechnology firms, biorepositories, and academic or private research institutions. Established in 1978, the company, originally known as Brooks Automation, Inc., officially became Azenta, Inc. in December 2021. Its corporate headquarters are located in Chelmsford, Massachusetts.
AZTA Company Deck
AZTA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call was mixed. Positive operational and recurring-revenue trends (strong biorepository growth, improved on-time delivery, faster RNA-Seq turnaround, solid cash position, and targeted cost savings) coexist with significant near-term challenges: organic revenue decline, notable margin compression, large goodwill impairments (~$149M), automated storage quality remediation and delayed large-capex orders, and a guidance reset lowering FY26 growth and profitability expectations. Management reiterated long-term conviction in strategic priorities and outlined actions (leadership changes, ABS deployment, cost reductions, M&A integration) to address execution gaps, but near-term results and uncertainty weighed on the quarter.View all AZTA earnings summariesAZTA Stock 12 Month Forecast
Average Price Target
$29.33
▲(4.09% Upside)
Technical Analysis
Ownership Overview
11.54% Insiders
35.60% Mutual Funds
19.18% Other Institutional Investors
4.93% Public Companies and
Individual Investors